Pfizer plans to move a reworked, once-a-day version of its weight-loss pill danuglipron into clinical trials later this year, the company said on Thursday, after scrapping a twice-daily version of the drug late last year.The new drug is part of the second generation of weight-loss pills under development by companies including Eli Lillyand Novo Nordisk that will offer patients a more convenient alternative to injections.Some analysts expect the weight-loss drug market, currently dominated by Novo Nordisk’s ...